FATE stock forecast
Our latest prediction for Fate Therapeutics, Inc.'s stock price was made on the Oct. 15, 2019 when the stock price was at 14.75$.
In the short term (2weeks), FATE's stock price should outperform the market by 0.74%. During that period the price should oscillate between -8.21% and +10.91%.
In the medium term (3months), FATE's stock price should outperform the market by 1.94%. During that period the price should oscillate between -18.83% and +29.92%.Get email alerts
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
At the moment the company generates 8M USD in revenues.
On its last earning announcement, the company reported a loss of -1.21$ per share.
The book value per share is 0.97$
Three months stock forecastOct. 15, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|